<DOC>
	<DOCNO>NCT01524341</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability PK uncomplicated adult malaria patient P. vivax P. falciparum infection 3 day dose KAE609 30 mg/day</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pharmacokinetics KAE609 Adult Patients With Acute , Uncomplicated Plasmodium Falciparum Vivax Malaria Mono-infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<criteria>Male female patient age 20 60 year Presence monoinfection P. falciparum P. vivax Weight 40 kg 90 kg Patients sign symptom severe/complicated malaria Mixed Plasmodium infection Presence serious chronic clinical condition require hospitalization . Severe malnutrition Significant chronic medical condition opinion investigator preclude enrollment study Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Acute malaria</keyword>
	<keyword>KAE609</keyword>
</DOC>